These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 28838265)

  • 81. Preoperative nutritional risk assessment in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for colorectal carcinomatosis.
    Banaste N; Rousset P; Mercier F; Rieussec C; Valette PJ; Glehen O; Passot G
    Int J Hyperthermia; 2018 Aug; 34(5):589-594. PubMed ID: 28828897
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Cytoreduction with hyperthermic intraperitoneal chemotherapy: an appraisal of outcomes and cost at a newly established peritoneal malignancy program.
    Hinkle NM; MacDonald J; Sharpe JP; Dickson P; Deneve J; Munene G
    Am J Surg; 2016 Sep; 212(3):413-8. PubMed ID: 27086201
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies.
    Kusamura S; Baratti D; Deraco M
    Ann Surg; 2012 Feb; 255(2):348-56. PubMed ID: 22202584
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion in Adolescent and Young Adults with Peritoneal Metastases.
    Dhir M; Ramalingam L; Shuai Y; Pakrafter S; Jones HL; Hogg ME; Zureikat AH; Holtzman MP; Ahrendt SA; Bahary N; Pingpank JF; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2017 Apr; 24(4):875-883. PubMed ID: 27995449
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.
    Vaira M; Robella M; Mellano A; Sottile A; De Simone M
    Int J Hyperthermia; 2014 Dec; 30(8):565-9. PubMed ID: 25430988
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Abdominal wall reconstruction after cytoreduction surgery-hyperthermic intraperitoneal chemotherapy.
    Scholer AJ; Oliver JB; Rosado J; Patel JS; Lynch LJ; Spiegler KM; Houck K; Chokshi RJ
    J Surg Res; 2018 Jan; 221():266-274. PubMed ID: 29229138
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study.
    Massari R; Barone M; Basilico R; Carella C; Colasante A; De Tursi M; Filippone A; Guetti L; Mani A
    Minerva Chir; 2014 Feb; 69(1):17-26. PubMed ID: 24675243
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Digestive fistulas after cytoreductive surgery & HIPEC in peritoneal carcinomatosis.
    Halkia E; Efstathiou E; Rogdakis A; Christakis C; Spiliotis J
    J BUON; 2015 May; 20 Suppl 1():S60-3. PubMed ID: 26051334
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Limited synchronous hepatic resection does not compromise peri-operative outcomes or survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Saxena A; Valle SJ; Liauw W; Morris DL
    J Surg Oncol; 2017 Mar; 115(4):417-424. PubMed ID: 28181257
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The 7th Edition of the AJCC Staging Classification Correlates with Biologic Behavior of Mucinous Appendiceal Tumor with Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Milovanov V; Sardi A; Studeman K; Nieroda C; Sittig M; Gushchin V
    Ann Surg Oncol; 2016 Jun; 23(6):1928-33. PubMed ID: 26714951
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma.
    Tabrizian P; Franssen B; Jibara G; Sweeney R; Sarpel U; Schwartz M; Labow D
    J Surg Oncol; 2014 Dec; 110(7):786-90. PubMed ID: 25091997
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Cytoreduction and HIPEC in the treatment of "unconventional" secondary peritoneal carcinomatosis.
    Cardi M; Sammartino P; Mingarelli V; Sibio S; Accarpio F; Biacchi D; Musio D; Sollazzo B; Di Giorgio A
    World J Surg Oncol; 2015 Oct; 13():305. PubMed ID: 26493405
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Major Postoperative Complications Are a Risk Factor for Impaired Survival after CRS/HIPEC.
    Schneider MA; Eshmuminov D; Lehmann K
    Ann Surg Oncol; 2017 Aug; 24(8):2224-2232. PubMed ID: 28265776
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The Comprehensive Complication Index: a New Measure of the Burden of Complications After Hyperthermic Intraperitoneal Chemotherapy.
    Dumitra S; O'Leary M; Raoof M; Wakabayashi M; Dellinger TH; Han ES; Lee SJ; Lee B
    Ann Surg Oncol; 2018 Mar; 25(3):688-693. PubMed ID: 29260417
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The evaluation of morbidity in gastrointestinal tumor patients underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC).
    Aytin YE; Cakcak İE; Sağıroğlu T
    Turk J Surg; 2023 Mar; 39(1):17-26. PubMed ID: 37275924
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Feasibility and benefits of an enhanced recovery after surgery protocol for patients undergoing cytoreductive surgery and heated intraperitoneal chemotharpy: A single institution experience.
    Siddharthan R; Dewey E; Billingsley K; Gilbert E; Tsikitis VL
    Am J Surg; 2020 Jun; 219(6):1073-1075. PubMed ID: 31253353
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Increased Plasma Levels of Danger-Associated Molecular Patterns Are Associated With Immune Suppression and Postoperative Infections in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Leijte GP; Custers H; Gerretsen J; Heijne A; Roth J; Vogl T; Scheffer GJ; Pickkers P; Kox M
    Front Immunol; 2018; 9():663. PubMed ID: 29675023
    [TBL] [Abstract][Full Text] [Related]  

  • 98. CA-125: an inaccurate surveillance tool immediately after cytoreductive surgery and hyperthermic intraoperative chemotherapy (CRS-HIPEC)?
    Shannon NB; Tan GHC; Chia CS; Soo KC; Teo MCC
    Int J Hyperthermia; 2018 Aug; 34(5):585-588. PubMed ID: 28683587
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Predictors of Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Paredes AZ; Abdel-Misih S; Schmidt C; Dillhoff ME; Pawlik TM; Cloyd JM
    J Surg Res; 2019 Feb; 234():103-109. PubMed ID: 30527460
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Impact of Cytoreductive Surgery and HIPEC on Intraoperative Gastrointestinal Wall Thickness and Patient Outcomes.
    Chen MZ; Chan DL; Alshahrani MS; Altoukhi K; Alzahrani N; Morris DL
    Anticancer Res; 2020 May; 40(5):2865-2869. PubMed ID: 32366436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.